SRR8518208
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.470
- INFLAMMATORY_RESPONSE+0.430
- COMPLEMENT+0.420
- IL2_STAT5_SIGNALING+0.400
- KRAS_SIGNALING_UP+0.400
- BILE_ACID_METABOLISM+0.390
- IL6_JAK_STAT3_SIGNALING+0.390
- ANDROGEN_RESPONSE+0.380
- COAGULATION+0.380
- FATTY_ACID_METABOLISM+0.350
Top 10 suppressed
- MYC_TARGETS_V2-0.680
- E2F_TARGETS-0.540
- MYC_TARGETS_V1-0.540
- G2M_CHECKPOINT-0.500
- DNA_REPAIR-0.400
- MITOTIC_SPINDLE-0.350
- WNT_BETA_CATENIN_SIGNALING-0.150
- NOTCH_SIGNALING-0.090
- UNFOLDED_PROTEIN_RESPONSE-0.060
- SPERMATOGENESIS-0.030
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_YEQVW4ND | low-grade glioma | — | 0.905 |
| 2 | TCGA-75-6212-01A-11R-1755-07 | — | cohortA1 | 0.900 |
| 3 | BS_FJZPQZ2C | pleomorphic xanthoastrocytoma(PXA) | — | 0.900 |
| 4 | SRR8518286 | — | F | 0.897 |
| 5 | MDT-AP-0226 | Med | Medulloblastoma | 0.888 |
| 6 | MDT-AP-2774 | Med | Medulloblastoma | 0.884 |
| 7 | BS_8VAZSJEN | pilocytic astrocytoma | — | 0.884 |
| 8 | MDT-AP-0385 | Med | Medulloblastoma | 0.884 |
| 9 | BS_GWCRMKE6 | pilocytic astrocytoma | — | 0.883 |
| 10 | TCGA-67-3772-01A-01R-0946-07 | — | cohortA1 | 0.881 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.470 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.430 | Idelalisib | — uncovered |
| COMPLEMENT | 0.420 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.400 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.400 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.390 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.390 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.380 | Inavolisib | — uncovered |
| COAGULATION | 0.380 | Binimetinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.350 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.350 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.350 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.340 | Cobimetinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.340 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.330 | Inavolisib | — uncovered |
| HYPOXIA | 0.300 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.290 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.270 | Idelalisib | — uncovered |
| PEROXISOME | 0.270 | Idelalisib | — uncovered |